Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Intrinsic Value
Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of GLUE.
Fundamental Analysis
Balance Sheet Decomposition
Monte Rosa Therapeutics Inc
| Current Assets | 236.2m |
| Cash & Short-Term Investments | 232.4m |
| Receivables | 505k |
| Other Current Assets | 3.3m |
| Non-Current Assets | 67.5m |
| PP&E | 62.6m |
| Other Non-Current Assets | 4.9m |
| Current Liabilities | 46.6m |
| Accounts Payable | 11.2m |
| Accrued Liabilities | 17.8m |
| Other Current Liabilities | 17.7m |
| Non-Current Liabilities | 77.9m |
| Other Non-Current Liabilities | 77.9m |
Earnings Waterfall
Monte Rosa Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-143.3m
USD
|
|
Operating Income
|
-143.3m
USD
|
|
Other Expenses
|
8m
USD
|
|
Net Income
|
-135.4m
USD
|
Free Cash Flow Analysis
Monte Rosa Therapeutics Inc
GLUE Profitability Score
Profitability Due Diligence
Monte Rosa Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Monte Rosa Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
GLUE Solvency Score
Solvency Due Diligence
Monte Rosa Therapeutics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Monte Rosa Therapeutics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GLUE Price Targets Summary
Monte Rosa Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for GLUE is 17.17 USD with a low forecast of 11.11 USD and a high forecast of 23.1 USD.
Ownership
GLUE Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
GLUE Price
Monte Rosa Therapeutics Inc
| Average Annual Return | -32.76% |
| Standard Deviation of Annual Returns | 41.18% |
| Max Drawdown | -94% |
| Market Capitalization | 274.3m USD |
| Shares Outstanding | 50 154 100 |
| Percentage of Shares Shorted | 6.25% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company is headquartered in Boston, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2021-06-24. The company is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops a protein degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN), that enables it to identify protein targets and molecular glue degrader (MGD), product candidates that are designed to eliminate therapeutically relevant proteins. The company focuses on therapeutic targets backed by biological and genetic rationale discovering and developing novel precision medicines. Its lead product candidate is MRT-2359, which is an orally bioavailable degrader of the translation termination factor protein GSPT1 in development initially for use in the treatment of cancers. Its programs are focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways.
You don't have any saved screeners yet
